

Project Brief: PROMISE

Full Title of Study/Programme	PROMISE (Preparing for Ring Opportunities through Market Introduction Support and knowledge Exchange)
Technical Focus Area/Key Words	Support early product introduction for the dapivirine ring through the Envision FP mechanism with the express goal of shaping the market and establishing a service delivery platform for future MPT VRs.
Summary paragraph (max 200 words)	We propose to support early product introduction for the dapivirine ring through the Envision FP mechanism with the express goal of shaping the market and establishing a service delivery platform for future MPT VRs. The activity will be called PROMISE (Preparing for Ring Opportunities through Market Introduction Support and knowledge Exchange). The draft scope of work outlined below is well aligned with Aim 3 of Envision FP (develop new methods to address method-related nonuse or fill gaps). During the first four years of Envision FP, FHI 360 established a robust pipeline of contraceptive products that will be introduced in LMIC in the coming years. Product introduction experience with the dapivirine ring will have direct cross-learning relevance to these contraceptive products given the primary service delivery channel for the ring is family planning settings.
Primary Objectives	<ol style="list-style-type: none"> 1. Support IPM’s service delivery channels analysis and strategy by further researching ways to integrate the dapivirine ring with family planning services and create an enabling environment for future de-medicalized delivery of the DVR in 5 countries engaging both FP and PrEP stakeholders (Note: this work will map out integrated and de-medicalized strategies that could strengthen health systems to deliver future VR products, e.g. 90-day DVR, dapivirine-levonorgestrel VR) 2. Convene a Regional Ring Collaborative for national planning and programming in 5 countries (note: this work will break down existing siloes between FP and PrEP national programming efforts and pave the path for future DVR programming at the national level) 3. Support IPM’s demand creation work by conducting market shaping activities to build awareness, acceptance, and demand for DVRs as an additional method choice to meet women’s sexual and reproductive health needs, engaging both FP and PrEP stakeholders (note: this work will create an enabling environment for the sustainability of VRs as a drug delivery platform for future VR products, e.g. 90-day DVR, dapivirine-levonorgestrel VR) 4. Knowledge management for ring (note: this work will strive to frame ring as part of a broader sexual

	reproductive health prevention narrative inclusive of FP and PrEP)
Secondary Objectives	Not Applicable
Primary Endpoint/Outcome	Market prepared for the introduction of the ring; namely in the areas of national-level policy, planning and coordination and knowledge management and dissemination. In addition, the market introduction program led by IPM and J&J Global Public Health in the areas of healthcare provider access and end-user access
Secondary Endpoint/Outcome	Not Applicable
Study Design	Technical Assistance Programme
Study arms	Not Applicable
Study population	Key stakeholders (including NDOH, implementing partners, civil society, end-users)
Study sample size	Not Applicable
Follow up/duration	Not Applicable
Study/Programme sites	National
Study/Programme duration	12 months (01 June 2020 – 31 May 2021)
Intervention	PROMISE will build on the four pillars of IPM and J&J's GPH access framework: (1) Government and Donor Support; (2) Operations and Logistics; (3) Clinical and Public Hospital (Health Care Provider) Access and (4) End-user Access. Specifically, the work under this framework aims to ensure: policy and funding support is secured for ring introduction at global and national levels; strategic and sound implementation partnership models are established; and community awareness-raising, end-user and healthcare provider education and demand creation activities are designed and pilot tested
Operations	Have regular weekly internal meetings; monthly calls with partners including donors
Investigators	Dr Saiqa Mullick, Diantha Pillay, Melanie Pleaner, El mari Briedenhann, Nkunda Vundamina
Other Partners & Collaborators	FHI360, LVCT Health, PZAT, IPM, JNJ GPH, Afton Bloom, Avenir Health
Sponsors/Donors	USAID
Linked Sub Studies and post grad projects	Not Applicable
Publications/key presentations to date	None
Progress Update	Positive EMA opinion for the ring received on 23 July 2020 Mission Concurrence for South Africa received on 18 September 2020 Planning for introductory meeting with NDOH to endorse PROMISE workplan Planning for key stakeholder meetings to provide input on delivery

	channels strategy and demand creation strategy
Frequency of donor narrative report	Quarterly partner reports and annual donor narrative with monthly updates
Overall Study/Project Contact	Diantha Pillay, Programme Manager, Wits Reproductive Health & HIV Institute (RHI), South Africa, Phone: +27 11 358 5363, Email: dpillay@wrhi.ac.za
Briefing owner and date	Diantha Pillay, 16 Oct 2020